{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:07:45Z","timestamp":1783786065055,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T00:00:00Z","timestamp":1211846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T00:00:00Z","timestamp":1211846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1038\/ncprheum0825","type":"journal-article","created":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T15:42:32Z","timestamp":1211902952000},"page":"364-370","source":"Crossref","is-referenced-by-count":15,"title":["Drug Insight: anti-tumor necrosis factor therapies for the vasculitic diseases"],"prefix":"10.1038","volume":"4","author":[{"given":"Carol A","family":"Langford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,27]]},"reference":[{"key":"BFncprheum0825_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/ard.2006.064279","volume":"66","author":"JA van Laar","year":"2007","unstructured":"van Laar JA et al. (2007) Adalimumab: a new modality for Beh\u00e7et's disease? Ann Rheum Dis 66: 565\u2013566","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0825_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s10067-006-0375-2","volume":"26","author":"MM Ahmed","year":"2007","unstructured":"Ahmed MM et al. (2007) Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 26: 1353\u20131355","journal-title":"Clin Rheumatol"},{"key":"BFncprheum0825_CR3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/sj.eye.6702352","volume":"21","author":"B Mushtaq","year":"2007","unstructured":"Mushtaq B et al. (2007) Adalimumab for sight-threatening uveitis in Beh\u00e7et's disease. Eye 21: 824\u2013825","journal-title":"Eye"},{"key":"BFncprheum0825_CR4","first-page":"304","volume":"24","author":"F Tato","year":"2005","unstructured":"Tato F et al. (2005) Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 24: 304\u2013307","journal-title":"Int Angiol"},{"key":"BFncprheum0825_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1056\/NEJMra022694","volume":"349","author":"CM Weyand","year":"2003","unstructured":"Weyand CM and Goronzy JJ (2003) Medium- and large-vessel vasculitis. N Engl J Med 349: 160\u2013169","journal-title":"N Engl J Med"},{"key":"BFncprheum0825_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1196\/annals.1358.023","volume":"1062","author":"CM Weyand","year":"2005","unstructured":"Weyand CM et al. (2005) Vascular dendritic cells in giant cell arteritis. Ann NY Acad Sci 1062: 195\u2013208","journal-title":"Ann NY Acad Sci"},{"key":"BFncprheum0825_CR7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1681\/ASN.2005101048","volume":"17","author":"JC Jennette","year":"2006","unstructured":"Jennette JC et al. (2006) Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 17: 1235\u20131242","journal-title":"J Am Soc Nephrol"},{"key":"BFncprheum0825_CR8","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1182\/blood-2005-05-1875","volume":"107","author":"E Csernok","year":"2006","unstructured":"Csernok E et al. (2006) Wegener autoantigen induces maturation of dendritic cells and licenses them for TH1 priming via the protease-activated receptor-2 pathway. Blood 107: 4440\u20134448","journal-title":"Blood"},{"key":"BFncprheum0825_CR9","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","volume":"160","author":"BR Ludviksson","year":"1998","unstructured":"Ludviksson BR et al. (1998) Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced TH1-type T cell cytokine pattern: reversal with IL-10. J Immunol 160: 3602\u20133609","journal-title":"J Immunol"},{"key":"BFncprheum0825_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00296-006-0281-6","volume":"27","author":"S Pay","year":"2007","unstructured":"Pay S et al. (2007) Immunopathogenesis of Beh\u00e7et's disease with special emphasis on the possible role of antigen presenting cells. Rheumatol Int 27: 417\u2013424","journal-title":"Rheumatol Int"},{"key":"BFncprheum0825_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clim.2005.09.010","volume":"118","author":"NK Tripathy","year":"2006","unstructured":"Tripathy NK et al. (2006) High TNF-\u03b1 and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. Clin Immunol 118: 154\u2013158","journal-title":"Clin Immunol"},{"key":"BFncprheum0825_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","volume":"44","author":"JH Stone","year":"2001","unstructured":"Stone JH et al. (2001) Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 44: 1149\u20131154","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0825_CR13","doi-asserted-by":"crossref","unstructured":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351\u2013361","DOI":"10.1056\/NEJMoa041884"},{"key":"BFncprheum0825_CR14","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/art.21869","volume":"54","author":"JH Stone","year":"2006","unstructured":"Stone JH et al. (2006) Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54: 1608\u20131618","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0825_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1517\/14712598.7.4.521","volume":"7","author":"PM Aries","year":"2007","unstructured":"Aries PM et al. (2007) Biological therapies: new treatment options for ANCA-associated vasculitis? Expert Opin Biol Ther 7: 521\u2013533","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 4","key":"BFncprheum0825_CR16","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1136\/ard.2005.042416","volume":"64","author":"C Mukhtyar","year":"2005","unstructured":"Mukhtyar C and Luqmani R (2005) Current state of tumour necrosis factor \u03b1 blockade in Wegener's granulomatosis. Ann Rheum Dis 64 (Suppl 4): S31\u2013S36","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0825_CR17","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","volume":"41","author":"P Lamprecht","year":"2002","unstructured":"Lamprecht P et al. (2002) Effectiveness of TNF-\u03b1 blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41: 1303\u20131307","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0825_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1136\/ard.61.6.559","volume":"61","author":"AD Booth","year":"2002","unstructured":"Booth AD et al. (2002) Safety and efficacy of TNF\u03b1 blockade in relapsing vasculitis. Ann Rheum Dis 61: 559","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0825_CR19","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","volume":"41","author":"P Bartolucci","year":"2002","unstructured":"Bartolucci P et al. (2002) Efficacy of the anti-TNF-\u03b1 antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41: 1126\u20131132","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0825_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","volume":"15","author":"A Booth","year":"2004","unstructured":"Booth A et al. (2004) Prospective study of TNF\u03b1 blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15: 717\u2013721","journal-title":"J Am Soc Nephrol"},{"key":"BFncprheum0825_CR21","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1002\/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y","volume":"44","author":"F Cantini","year":"2001","unstructured":"Cantini F et al. (2001) Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44: 2933\u20132935","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0825_CR22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1136\/ard.62.11.1116","volume":"62","author":"AP Andonopoulos","year":"2003","unstructured":"Andonopoulos AP et al. (2003) Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 62: 1116","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0825_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/rheumatology\/41.3.347","volume":"41","author":"P Airo","year":"2002","unstructured":"Airo P et al. (2002) Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 41: 347\u2013349","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0825_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/ard.62.4.373","volume":"62","author":"AL Tan","year":"2003","unstructured":"Tan AL et al. (2003) Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 62: 373\u2013374","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0825_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"GS Hoffman","year":"2007","unstructured":"Hoffman GS et al. (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146: 621\u2013630","journal-title":"Ann Intern Med"},{"key":"BFncprheum0825_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","volume":"146","author":"C Salvarani","year":"2007","unstructured":"Salvarani C et al. (2007) Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 146: 631\u2013639","journal-title":"Ann Intern Med"},{"key":"BFncprheum0825_CR27","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/art.20300","volume":"50","author":"GS Hoffman","year":"2004","unstructured":"Hoffman GS et al. (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50: 2296\u20132304","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0825_CR28","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/rheumatology\/keh661","volume":"44","author":"RossaA Della","year":"2005","unstructured":"Della Rossa A et al. (2005) Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford) 44: 1074\u20131075","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0825_CR29","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s10067-006-0227-0","volume":"26","author":"ZT Karageorgaki","year":"2007","unstructured":"Karageorgaki ZT et al. (2007) Infliximab in Takayasu arteritis: a safe alternative? Clin Rheumatol 26: 984\u2013987","journal-title":"Clin Rheumatol"},{"key":"BFncprheum0825_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/01.rhu.0000173218.28013.3e","volume":"11","author":"M Jolly","year":"2005","unstructured":"Jolly M and Curran JJ (2005) Infliximab-responsive uveitis and vasculitis in a patient with Takayasu arteritis. J Clin Rheumatol 11: 213\u2013215","journal-title":"J Clin Rheumatol"},{"key":"BFncprheum0825_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2169\/internalmedicine.45.1377","volume":"45","author":"F Tanaka","year":"2006","unstructured":"Tanaka F et al. (2006) Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 45: 313\u2013316","journal-title":"Intern Med"},{"key":"BFncprheum0825_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"PP Sfikakis","year":"2004","unstructured":"Sfikakis PP et al. (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades\u2013Beh\u00e7et disease. Ann Intern Med 140: 404\u2013406","journal-title":"Ann Intern Med"},{"key":"BFncprheum0825_CR33","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Niccoli","year":"2007","unstructured":"Niccoli L et al. (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et's disease: a 24-month follow-up study. Rheumatology (Oxford) 46: 1161\u20131164","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0825_CR34","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I et al. (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease: an open-label trial. Arthritis Rheum 52: 2478\u20132484","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0825_CR35","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S et al. (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis. J Rheumatol 31: 1362\u20131368","journal-title":"J Rheumatol"},{"key":"BFncprheum0825_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","volume":"26","author":"AM Abu El-Asrar","year":"2005","unstructured":"Abu El-Asrar AM et al. (2005) Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et's disease. Int Ophthalmol 26: 83\u201392","journal-title":"Int Ophthalmol"},{"key":"BFncprheum0825_CR37","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1196\/annals.1423.050","volume":"1110","author":"S Tognon","year":"2007","unstructured":"Tognon S et al. (2007) Anti-TNF-alpha therapy in seven patients with Beh\u00e7et's uveitis: advantages and controversial aspects. Ann NY Acad Sci 1110: 474\u2013484","journal-title":"Ann NY Acad Sci"},{"key":"BFncprheum0825_CR38","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/sj.eye.6701689","volume":"19","author":"JM Benitez-del-Castillo","year":"2005","unstructured":"Benitez-del-Castillo JM et al. (2005) Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 19: 841\u2013845","journal-title":"Eye"},{"key":"BFncprheum0825_CR39","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M et al. (2005) Short-term trial of etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study. J Rheumatol 32: 98\u2013105","journal-title":"J Rheumatol"},{"key":"BFncprheum0825_CR40","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s10067-006-0410-3","volume":"26","author":"JH Ju","year":"2007","unstructured":"Ju JH et al. (2007) Successful treatment of life-threatening intestinal ulcer in Beh\u00e7et's disease with infliximab: rapid healing of Beh\u00e7et's ulcer with infliximab. Clin Rheumatol 26: 1383\u20131385","journal-title":"Clin Rheumatol"},{"key":"BFncprheum0825_CR41","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s10350-006-0813-x","volume":"50","author":"JS Byeon","year":"2007","unstructured":"Byeon JS et al. (2007) Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Beh\u00e7et's disease: report of a case. Dis Colon Rectum 50: 672\u2013676","journal-title":"Dis Colon Rectum"},{"key":"BFncprheum0825_CR42","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s10067-006-0426-8","volume":"26","author":"LM Endo","year":"2007","unstructured":"Endo LM et al. (2007) Pulmonary aneurysms and intracardiac thrombi due to Beh\u00e7et's disease in an African-American adolescent with oculocutaneous albinism. Clin Rheumatol 26: 1537\u20131539","journal-title":"Clin Rheumatol"},{"key":"BFncprheum0825_CR43","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1136\/ard.2005.045195","volume":"65","author":"K Baki","year":"2006","unstructured":"Baki K et al. (2006) Beh\u00e7et's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis 65: 1531\u20131532","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0825_CR44","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/ard.2006.056804","volume":"66","author":"K Fujikawa","year":"2007","unstructured":"Fujikawa K et al. (2007) Successful treatment of refractory neuro-Beh\u00e7et's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 66: 136\u2013137","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0825_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.clineuro.2006.11.002","volume":"109","author":"JE Alty","year":"2007","unstructured":"Alty JE et al. (2007) A patient with neuro-Beh\u00e7et's disease is successfully treated with etanercept: further evidence for the value of TNF\u03b1 blockade. Clin Neurol Neurosurg 109: 279\u2013281","journal-title":"Clin Neurol Neurosurg"},{"key":"BFncprheum0825_CR46","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","volume":"46","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP et al. (2007) Anti-TNF therapy in the management of Beh\u00e7et's disease\u2014review and basis for recommendations. Rheumatology (Oxford) 46: 736\u2013741","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0825_CR47","first-page":"1241","volume":"31","author":"JT Rosenbaum","year":"2004","unstructured":"Rosenbaum JT (2004) Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Beh\u00e7et's disease. J Rheumatol 31: 1241\u20131243","journal-title":"J Rheumatol"},{"key":"BFncprheum0825_CR48","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpeds.2004.12.022","volume":"146","author":"JC Burns","year":"2005","unstructured":"Burns JC et al. (2005) Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 146: 662\u2013667","journal-title":"J Pediatr"},{"key":"BFncprheum0825_CR49","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/03009740600588228","volume":"35","author":"EV Stenbog","year":"2006","unstructured":"Stenbog EV et al. (2006) The effect of TNF\u03b1 blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol 35: 318\u2013321","journal-title":"Scand J Rheumatol"},{"key":"BFncprheum0825_CR50","first-page":"808","volume":"31","author":"JE Weiss","year":"2004","unstructured":"Weiss JE et al. (2004) Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31: 808\u2013810","journal-title":"J Rheumatol"},{"key":"BFncprheum0825_CR51","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1078\/0171-2985-00197","volume":"206","author":"O Arbach","year":"2002","unstructured":"Arbach O et al. (2002) Treatment of refractory Churg\u2013Strauss Syndrome (CSS) by TNF-alpha blockade. Immunobiology 206: 496\u2013501","journal-title":"Immunobiology"},{"key":"BFncprheum0825_CR52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/01.rhu.0000120897.08819.ac","volume":"10","author":"A Tiliakos","year":"2004","unstructured":"Tiliakos A et al. (2004) The use of infliximab in a patient with steroid-dependent Churg\u2013Strauss syndrome. J Clin Rheumatol 10: 96\u201397","journal-title":"J Clin Rheumatol"},{"key":"BFncprheum0825_CR53","first-page":"1371","volume":"32","author":"J Al-Bishri","year":"2005","unstructured":"Al-Bishri J et al. (2005) Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 32: 1371\u20131373","journal-title":"J Rheumatol"},{"key":"BFncprheum0825_CR54","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfk082","volume":"21","author":"K Wu","year":"2006","unstructured":"Wu K and Throssell D (2006) A new treatment for polyarteritis nodosa. Nephrol Dial Transplant 21: 1710\u20131712","journal-title":"Nephrol Dial Transplant"},{"key":"BFncprheum0825_CR55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1468-3083.2006.01967.x","volume":"21","author":"J Vega Gutierrez","year":"2007","unstructured":"Vega Gutierrez J et al. (2007) Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab. J Eur Acad Dermatol Venereol 21: 570\u2013571","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"BFncprheum0825_CR56","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jaad.2004.01.003","volume":"51","author":"R Mang","year":"2004","unstructured":"Mang R et al. (2004) Therapy for severe necrotizing vasculitis with infliximab. J Am Acad Dermatol 51: 321\u2013322","journal-title":"J Am Acad Dermatol"},{"key":"BFncprheum0825_CR57","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaad.2005.02.009","volume":"53","author":"IW Uthman","year":"2005","unstructured":"Uthman IW et al. (2005) Response of deep cutaneous vasculitis to infliximab. J Am Acad Dermatol 53: 353\u2013354","journal-title":"J Am Acad Dermatol"},{"key":"BFncprheum0825_CR58","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/keh080","volume":"43","author":"MO Chandesris","year":"2004","unstructured":"Chandesris MO et al. (2004) Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia. Rheumatology (Oxford) 43: 532\u2013533","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0825_CR59","unstructured":"ClinicalTrials.gov [ http:\/\/www.clinicaltrials.gov ]"}],"container-title":["Nature Clinical Practice Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0825.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0825","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0825.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T12:41:56Z","timestamp":1738240916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncprheum0825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,27]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["BFncprheum0825"],"URL":"https:\/\/doi.org\/10.1038\/ncprheum0825","relation":{},"ISSN":["1745-8382","1745-8390"],"issn-type":[{"value":"1745-8382","type":"print"},{"value":"1745-8390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,27]]}}}